The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
Open accessAbstract
BACKGROUND: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease. METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received the study treatment for 52 weeks. The coprimary outcomes were scores on the SMMSE and on the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 0 to 60, with higher scores indicating greater impairment). The minimum clinically important differences were 1.4 points on the SMMSE and 3.5 points on the BADLS. RESULTS: Patients assigned to continue donepezil, as compared with those assigned to discontinue donepezil, had a score on the SMMSE that was higher by an average of 1.9 points (95% confidence interval [CI], 1.3 to 2.5) and a score on the BADLS that was lower (indicating less impairment) by 3.0 points (95% CI, 1.8 to 4.3) (P<0.001 for both comparisons). Patients assigned to receive memantine, as compared with those assigned to receive memantine placebo, had a score on the SMMSE that was an average of 1.2 points higher (95% CI, 0.6 to 1.8; P<0.001) and a score on the BADLS that was 1.5 points lower (95% CI, 0.3 to 2.8; P=0.02). The efficacy of donepezil and of memantine did not differ significantly in the presence or absence of the other. There were no significant benefits of the combination of donepezil and memantine over donepezil alone. CONCLUSIONS: In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months. (Funded by the U.K. Medical Research Council and the U.K. Alzheimer's Society; Current Controlled Trials number, ISRCTN49545035.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In moderate and severe AD, short-term efficacy of memantine monotherapy compared with placebo is reported in several RCTs of 12 to 50 weeks duration and supported by meta-analyses.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700
ANew Look at the Statistical Model Identification
AKAlKE, H. (2011) · Cited by 4,177
The Validity of Two Versions of the GHQ in the WHO Study of Mental Illness in General Health Care
GOLDBERG, D. P., GATER, R., SARTORIUS, N., USTUN, T. B., PICCINELLI, M., GUREJE, O., & RUTTER, C. (1997) · Psychological Medicine · doi:10.1017/s0033291796004242 · Cited by 3,657
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Smith, S. C., Lamping, D. L., Banerjee, S., Harwood, R., Foley, B., Smith, P. B., Cook, J., Murray, J., Prince, M. J., Levin, E., et al. (2005) · Health Technology Assessment · doi:10.3310/hta9100 · Cited by 651
Flagged first, then by citations
1 of the 31 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Areosa SA, 2005, Cochrane Database Syst Rev, 3, CD003154
- Smith SC, 2005, Health Technol Assess, 9, 1
- 10.1097/00005650-200305000-00004 · DOI
Cited by
Sorted by citations
Items 501–600 of 787
de Hoyos-Alonso, M. C., Tapias-Merino, E., Barros, C. M. M., Sánchez-Martínez, M., & Otero, Á. (2015) · Neurología (English Edition) · doi:10.1016/j.nrleng.2014.02.005 · Cited by 3
Shaw, G. (2012) · Neurology Today · doi:10.1097/01.nt.0000414612.08062.70 · Cited by 3
Diabetes Associated Memory Impairment: Perspective on Management Strategies
Sharma, G., Sonu, & Harikumar, S. (2015) · International journal of pharma research and review · Cited by 3
Protocolo de diagnóstico y tratamiento del deterioro cognitivo
Barral, A. G., Barral, A. G., Alonso, M. ª. D. C. D. H., & Viñas, A. T. (2018) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2018.06.002 · Cited by 5
von Gunten, A., Nogueira, E. L., Parmentier, H., & Gomes, I. (2019) · Springer eBooks · doi:10.1007/978-3-030-10814-4_21 · Cited by 3
Ткачева, О. Н., Рунихина, Н. К., Mkhitaryan, E. A., Koberskaya, N. N., & Маневич, Т. М. (2020) · Russian neurological Journal · doi:10.30629/2658-7947-2019-24-5-54-60 · Cited by 3
Memantine and Alzheimer's disease
del Río‐Sancho, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00032-x · Cited by 3
Validation of the Chinese Version of the Relevant Outcome Scale for Alzheimer’s Disease (CROSA)
Zhang, S., Qi, J., Yang, Q., & Guo, Q. (2021) · International Psychogeriatrics · doi:10.1017/s1041610221000247 · Cited by 3
Current Research on Pro-drug Therapies for Parkinson's and Alzheimer's Disease
Huo, C., Wu, L., Jiang, Z., Yang, J., Wang, Z., Li, Y., & Qian, S. (2021) · Medicinal Chemistry · doi:10.2174/1573406418666211130150821 · Cited by 3
Digala, L. P., Murala, S., & Bollu, P. C. (2022) · Springer eBooks · doi:10.1007/978-3-031-07897-2_11 · Cited by 3
The Current Status of Drugs Related to Amyloid β-protein in Alzheimer's Disease
Zhu, Y. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.5792 · Cited by 3
Psychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_31 · Cited by 3
Discontinuing Donepezil or Starting Memantine for Alzheimer's Disease
Finucane, M. M., & Finucane, T. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1204656 · Cited by 3
Mental Health Interventions for the Elderly
Mikesell, L. (2021) · Springer eBooks · doi:10.1007/978-3-030-12852-4_8-1 · Cited by 3
Nkouonlack, C., Njamnshi, W. Y., Angwafor, S. A., Fodjo, J. N. S., Mengnjo, M. K., Ngarka, L., Mbede, M., Nfor, L. N., Abomate, C., Nganchfu, K., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2887319/v1 · Cited by 3
Combination Drug Therapy for the Management of Alzheimer’s Disease
Dudchenko, N. G., & Mkhitaryan, E. A. (2024) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-2-2024-140-144 · Cited by 2
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_139-1 · Cited by 3
Guardabassi, V., Maranesi, A., Massimo, M. M., Manoni, E., Cirilli, E., & Nicolini, P. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1569406 · Cited by 4
Antidementia drugs and nursing home placement: a systematic review and meta-analysis
Rattanatanyapat, P., Suan-ek, P., Saokaew, S., Phisalprapa, P., & Mongkhon, P. (2026) · European Geriatric Medicine · doi:10.1007/s41999-025-01398-3 · Cited by 3
Yang, D., Liu, L., & Fu, J. (2026) · Journal of Integrative Neuroscience · doi:10.31083/jin43410 · Cited by 2
Lu, C.-W., Ng, T.-C., Cheng, Y.-C., & Su, C.-H. (2026) · Healthcare · doi:10.3390/healthcare14050689 · Cited by 2
A paradigm of the diagnosis and treatment for the whole process of Alzheimer’s disease
Shi, J., Du, Y., Wang, H., Zhang, N., Chen, W., Ni, J., Lu, X., Sun, Y., Wang, G., Liu, J., et al. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2672193 · Cited by 3
Differential Diagnosis and Treatment of Chronic Traumatic Encephalopathy
Budson, A. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-54425-2.00009-6 · Cited by 2
Cholinesterase inhibitors in dementias
Mecocci, P., Paolacci, L., & Boccardi, V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00029-x
Pharmacological drug strategies in Alzheimer's Disease
Dantas, R. L. M., Baracho, N. C., Camins, A., & Ettcheto, M. (2021) · Revista Neurociências · doi:10.34024/rnc.2021.v29.12413 · Cited by 2
Drug discovery: Chaos can be your friend or your enemy
Miller, S. M., Moos, W. H., Munk, B. H., Munk, S. A., Hart, C. P., & Spellmeyer, D. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824304-6.00012-2 · Cited by 3
Conditioned Media Therapy in Alzheimer's Disease: Current Findings and Future Challenges
Firoozi, A., Shadi, M., Aghaei, Z., & Namavar, M. R. (2023) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x18666230523155659 · Cited by 2
Improving Clinical Trials of Antioxidants in Alzheimer’s Disease
Daly, T. P. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230308 · Cited by 2
ADVANCEMENT IN THE TREATMENT OF ALZHEIMER'S DISEASE, 2023
Safdar, A., Ghani, M. U., Sabar, M. F., Khan, M. U., Hussain, M., aziz, K., & Hussain, T. (2024) · International Journal of Pharmacy & Integrated Health Sciences · doi:10.56536/ijpihs.v5i1.114 · Cited by 2
Repurposing of biologics and biopharmaceuticals
Israr, J., Alam, S., Singh, V., & Kumar, A. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.028 · Cited by 2
Wang, G., Chen, T., O'Gorman, J. T., Li, Y., Li, C., Guizzetti, L., Mangal, B., Wang, W., Wu, S., Inman, D., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251352189 · Cited by 2
Dosa-Toader, G., Balard, P., Gonfrier, S., Marro, G., Guérin, O., & Sacco, G. (2014) · Les cahiers de l année gérontologique · doi:10.1007/s12612-014-0380-z · Cited by 2
Hausner, L., & Frölich, L. (2013) · Nervenheilkunde · doi:10.1055/s-0038-1633367 · Cited by 2
Alzheimer’s Dementia and Lifestyle: Towards a Primary Prevention
Walach, H., & Loef, M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6852-3_12 · Cited by 2
Safety and Efficacy of Memantine Extended-Release in the Management of Alzheimer's Disease
Corbett, A., Francis, P. T., & Ballard, C. G. (2013) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s7794 · Cited by 2
Micca, J. L., Galvin, J. E., Velting, D. M., & Meng, X. (2014) · SAGE Open Medicine · doi:10.1177/2050312114561569 · Cited by 2
Cholinesterase Inhibitors and Memantine in More Advanced Alzheimer’s Disease: The Debate Continues
Dwolatzky, T., & Clarfield, A. M. (2012) · Aging Health · doi:10.2217/ahe.12.24 · Cited by 2
Murayama-Sung, L., & Ahmed, I. I. K. (2014) · Springer eBooks · doi:10.1007/978-3-319-11005-9_33 · Cited by 2
PETIT, A.-É., Mangeard, H., Chazard, E., & Puisieux, F. (2016) · L Encéphale · doi:10.1016/j.encep.2015.03.006 · Cited by 2
Czapiewski, S., & Brown-Nyseth, V. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_2 · Cited by 2
Matsunaga, S., Kishi, T., & Iwata, N. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.07.020 · Cited by 2
Cholinesterase Inhibitors and Memantine in Adults with Alzheimer Disease
Santaguida, P. L., Shamliyan, T., & Goldmann, D. R. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.07.002 · Cited by 2
Computation of Pharmacologic Therapy Effects on Cognitive Abilities of Alzheimer’s Disease Patients
Saribudak, A., Subick, A. A., & Uyar, M. Ü. (2016) · IEEE International Conference on Bioinformatics and Bioengineering (BIBE) · doi:10.1109/bibe.2016.49 · Cited by 2
Miller, S. M., Moos, W. H., Munk, B. H., & Munk, S. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-08-100625-2.00010-6 · Cited by 3
Pharmacotherapy of Alzheimer disease and neuropsychiatric symptoms of dementia
Prokopová, I. (2018) · Psychiatrie pro praxi · doi:10.36290/psy.2018.014 · Cited by 2
Tratamiento de la enfermedad de Alzheimer
Luque, M. L., de León, J. M. R. S., Izquierdo, P., & García, C. F. (2011) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(11)70069-5 · Cited by 5
Nikolaeva, N. S., Maltsev, A. V., Овчинников, Р. К., Sokolov, V. B., Aksinenko, A. Y., Bovina, E. V., & Kinzirsky, A. S. (2019) · Biology Bulletin · doi:10.1134/s1062359019030075 · Cited by 2
Guo, P., Cao, C., Ma, Y., & Wang, J. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02337-9 · Cited by 3
Nanoceuticals as Theranostics Against Neurodegenerative Diseases
Mishra, P., & Anand, S. (2022) · Nutritional neurosciences · doi:10.1007/978-981-16-8158-5_14 · Cited by 2
Lange‐Asschenfeldt, C., & Benkert, O. (2020) · Springer eBooks · doi:10.1007/978-3-662-61753-3_6 · Cited by 2
Aga, V. M., Shad, M. U., Zhu, H., & Salzman, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-800136-3.00023-5 · Cited by 2
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_139 · Cited by 3
Pharmakologische Therapie der Alzheimer-Demenz: Aktueller Stand und Perspektiven
Müller, P., Fendt, M., & Müller, N. (2019) · Der Internist · Cited by 2
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg006 · Cited by 2
Hughes, J. C., & Williamson, T. (2019) · The Dementia Manifesto · doi:10.1017/9781316336229.011
Garnier‐Crussard, A., & Krolak‐Salmon, P. (2022) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2022.01.011 · Cited by 1
Chapter 20. Psychopharmacology
Mulsant, B. H., & Pollock, B. G. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375196.ds20 · Cited by 1
Geriatrisches Screening und Assessment bei chronischer Nierenkrankheit
Pommer, W., Weber, F., Fleig, S. V., Schäfer, H., Hahn, S., Romero, F., Affeldt, A. M., Grupp, C., Hoffmann, U., (DGfN), K. A. D. D. G. F. N., et al. (2025) · Die Nephrologie · doi:10.1007/s11560-024-00826-y · Cited by 1
Kim, S.-S., Kim, W., Moon, H., Oh, S., Hong, G.-S., Lee, B., Choi, C. W., Lee, B., Choi, J. S., & Kim, M. S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177645 · Cited by 1
Zhou, Y., Diwu, Y., Li, Y.-X., Zhang, J., Zhang, X., Li, S., Sun, T., & Zhang, Q. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04431-w · Cited by 1
Liu, Y., Ning, Z., Dai, Q., Zhang, X., Xiao, Y., Zhang, Z., Guo, D., Chen, J., Li, Y., Li, W., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.024 · Cited by 1
Gupta, R. A., Rajni, R., Shah, K., & Dewangan, H. K. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128387875250805042824 · Cited by 1
Almeida, O. P., Page, A. T., & Etherton‐Beer, C. (2026) · International Psychogeriatrics · doi:10.1016/j.inpsyc.2025.100182 · Cited by 1
Lecerf, S., Guinebretiere, O., Bentegeac, R., Gauthier, V., Aymes, E., Mekkaoui, C., Dumurgier, J., Amouyel, P., Durrleman, S., Nédelec, T., et al. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101607 · Cited by 1
Lisgaras, C. P., & Scharfman, H. E. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71154 · Cited by 1
Zhao, M., Qu, Y., Zhang, S., Zhang, M., Wang, H. H., Yang, Y., Gu, X. F., Hou, X., & Yan, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1707688 · Cited by 1
Zhao, Y., Luo, G., Huang, C., Chen, Z., Wei, Y., Chen, Q., Wang, F., Gan, Y., & Yin, X. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100564 · Cited by 1
Ganesh, A., Sujanthan, S., Muir, R. T., Joundi, R. A., Hill, M. D., Quinn, T. J., Menon, B. K., Sajobi, T. T., Rabin, J. S., Dainty, K. N., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.077180 · Cited by 1
Visible-light-induced synthesis of indanones via the annulation of α-hydroxy ketones and alkynes
Lv, J. F., Lang, Y., & Zeng, H. (2026) · Chemical Communications · doi:10.1039/d6cc03320b · Cited by 1
Management of Alzheimer’s Disease Using disease-modifying Drugs
Gauthier, S. G. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.37 · Cited by 1
Barriers to evidence-based prescribing in Alzheimer's disease
Ballard, C. G. (2013) · British Journal of Mental Health Nursing · doi:10.12968/bjmh.2013.2.1.16 · Cited by 2
Thorsen, N. V. (2016) · Cited by 1
Medicamenteuze behandeling van dementie
Koopmans, R. T. C. M., Rikkert, M. G. M. O., & Zuidema, S. U. (2017) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2048-6_3 · Cited by 1
Opportunities for Combination Trials
Ballard, C. G., & Corbett, A. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.17 · Cited by 1
Medications to Treat Neurodegenerative Diseases
Hill, A. M., Cutler, J. B. R., & Robinson, K. (2019) · Cambridge University Press eBooks · doi:10.1017/9781107706866.038 · Cited by 1
Validation Prognostic of the Baylor Profound Mental Status Examination
Ríos, S. S., Lozoya-Moreno, S., Plaza, L., Soler-Moratalla, I., Solís, J., & Abizanda, P. (2019) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000504168 · Cited by 1
Jelić, V., & Winblad, B. G. (2021) · Springer eBooks · doi:10.1007/978-3-030-77904-7_5 · Cited by 1
Pharmacological Management of Dementia—An Overview
Dikshit, R., Karia, S., Thakurdesai, A., Merchant, H., & Sousa, A. D. (2021) · Springer eBooks · doi:10.1007/978-981-16-3864-0_22 · Cited by 1
Larner, A. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-75259-4_10 · Cited by 1
Schwabe, U. (2013) · Springer eBooks · doi:10.1007/978-3-642-37124-0_10 · Cited by 1
Potocnik, F. C. V. (2013) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v19i3.944 · Cited by 1
Förstl, H. (2014) · Springer eBooks · doi:10.1007/978-3-642-54723-2_5 · Cited by 1
Barriers to evidence-based prescribing in Alzheimer's disease
Ballard, C. G. (2013) · British Journal of Mental Health Nursing · doi:10.12968/bjmh.2013.2.1.97534 · Cited by 1
Alzheimer’s Disease and Other Dementias
Neel, I. C. (2022) · Springer eBooks · doi:10.1007/978-3-030-01782-8_84-1 · Cited by 1
Capabilities of combined therapy of Alzheimer’s disease
Васенина, Е. Е., Veryugina, N. I., & Levin, O. S. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212211245 · Cited by 1
Kognitive Störungen und Demenz
Hoffmann, U. (2023) · Springer eBooks · doi:10.1007/978-3-662-65648-8_12 · Cited by 1
Lead Compounds for Brain Protection against Alzheimer’s
AlSalem, H., Al-Ghamdi, A. R., & Issa, I. S. (2023) · International Journal of Science and Research Archive · doi:10.30574/ijsra.2023.10.1.0214 · Cited by 1
Jeyakumar, M., Balan, D. J., Kiruthiga, C., Jafni, S., & Devi, K. P. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23580 · Cited by 1
Maldonado, J. R., & Sher, Y. I. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_81-1 · Cited by 1
Neurologic Disease and Anesthesia
Du, A., Culley, D. J., & Crosby, G. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93273-8.00025-0 · Cited by 1
Photoredox‐Catalyzed [3+2] annulation of Aromatic Amides with Olefins via Iminium Intermediates
Tang, Z., Yao, Z., Yu, Y., Huang, J., Ma, X., Zhao, X., Chang, Z., & Zhao, D. (2024) · Angewandte Chemie · doi:10.1002/ange.202412152 · Cited by 1
Lee, Y., Shi, S., Sison, S. D. M., Park, C. M., Oh, G., Jeong, S., McCarthy, E. P., & Kim, D. H. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.45878 · Cited by 2
Safety and effectiveness of Donepezil and Memantine in Alzheimer's Disease
Ghosh, A. (2025) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2025.170310
PREVENTING LOSS OF INDEPENDENCE THROUGH EXERCISE (PLIE) FOR OLDER ADULTS WITH DEMENTIA
Barnes, D., Chesney, M. A., Yaffe, K. S., Flores, C., Wu, E. Y., & Mehling, W. E. (2012) · eScholarship (California Digital Library) · Cited by 1
Alzheimer’s Disease: A Clinical Perspective
Xu, W., Marseglia, A., Ferrari, C., & Wang, H. (2013) · InTech eBooks · doi:10.5772/54539 · Cited by 2
Alzheimer Disease and Other Dementias
Whalen, R. M. (2020) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_25-2 · Cited by 1
Ask the Expert: Cognitive Decline
Walaszek, A. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.55 · Cited by 1
Advances in Therapies and Scope for Personalized Medicine in Alzheimer’s Disease
Ravishankar, H. N., Dutta, A. K., Lewis, A. G., & Mohan, A. (2016) · Personalized Medicine · doi:10.2217/pme.15.49 · Cited by 1
Memantine: from the original brand to generics
Titova, N. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2017117101136-143 · Cited by 1
Pharmacotherapy of Alzheimer disease and neuropsychiatric symptoms of dementia
Prokopová, I. (2018) · Psychiatrie pro praxi · doi:10.36290/psy.2018.002 · Cited by 1
Metadata
- Authors
- Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., Hughes, A., Jacoby, R., Jones, R., Jones, R., McKeith, I., Macharouthu, A., O'Brien, J., Passmore, P., Sheehan, B., Juszczak, E., Katona, C., Hills, R., Knapp, M., Ballard, C., Brown, R., Banerjee, S., Onions, C., Griffin, M., Adams, J., Gray, R., Johnson, T., Bentham, P., & Phillips, P.
- Affiliations
- King's College London (GB)
- Churchill Hospital (GB)
- University of Leicester (GB)
- Whiston Hospital (GB)
- Newcastle University (GB)
- University of Manchester (GB)
- Fulbourn Hospital (GB)
- University of Oxford (GB)
- Inverclyde Royal Hospital (GB)
- Crichton Royal Hospital (GB)
- Queen's University Belfast (GB)
- University of Warwick (GB)
- University College London (GB)
- University of Wales (GB)
- Avon and Wiltshire Mental Health Partnership NHS Trust (GB)
- University of Cambridge (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- ORCID
- Howard, Robert
- McShane, Rupert
- Ritchie, Craig
- Baldwin, Ashley
- Barber, Robert
- Burns, Alistair
- Dening, Tom
- Findlay, David
- Holmes, Clive
- Jones, Roy
- McKeith, Ian
- Macharouthu, Ajay
- O'Brien, John
- Passmore, Peter
- Sheehan, Bart
- Juszczak, Edmund
- Katona, Cornelius
- Hills, Robert
- Knapp, Martin
- Ballard, Clive
- Brown, Richard
- Banerjee, Sube
- Gray, Richard
- Johnson, Tony
- Bentham, Peter
- Phillips, Patrick
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-08
- Volume
- 366
- Issue
- 10
- Pages
- 893-903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2151585937
- Cited by
- 782
- References
- 31
- Citations by year
- 2026: 43 · 2025: 49 · 2024: 44 · 2023: 58 · 2022: 51 · 2021: 48 · 2020: 45 · 2019: 58 · 2018: 47 · 2017: 55 · 2016: 54 · 2015: 54 · 2014: 59 · 2013: 74 · 2012: 40
- FWCI
- 52.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
- Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
- Leicester Research Archive (University of Leicester) (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Sussex Research Online (University of Sussex) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Alzheimer's Society
- King's College London
- Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, donepezil, memantine, cholinesterase inhibitors, NMDA receptor antagonists, combination therapy, cognitive function, activities of daily living, functional disability, treatment continuation, community-dwelling patients, minimal clinically important difference, treatment discontinuation
- MeSH terms
- Donepezil, Aged, Aged, 80 and over, Alzheimer Disease, Cholinesterase Inhibitors, Double-Blind Method, Drug Synergism, Drug Therapy, Combination, Female, Humans, Indans, Male, Memantine, Patient Dropouts, Piperidines, Psychological Tests, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Excitatory Amino Acid Antagonists, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
